biotech / news / / Anchorage Daily News
The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid.
Regeneron will lower the prices of all current and future drugs on Medicaid under this deal.
KEY POINTS
- Regeneron agreed to sell Praluent for $225 via the TrumpRx discounted drug website.
- Regeneron will invest $27 billion in U.S. research, development, and manufacturing per the new agreement.
- Regeneron's Otarmeni gene therapy for congenital hearing loss was FDA-approved and will be free to eligible U.S. patients.
- The FDA's expedited approval of Otarmeni used the controversial Commissioner's National Priority Voucher program.
COMPANIES
Summarized by Newsio from Anchorage Daily News. How we summarize →